Journal article
Cognitive impairment in first-episode mania: a systematic review of the evidence in the acute and remission phases of the illness
Rothanthi Daglas, Murat Yucel, Sue Cotton, Kelly Allott, Sarah Hetrick, Michael Berk
INTERNATIONAL JOURNAL OF BIPOLAR DISORDERS | SPRINGER | Published : 2015
Abstract
There is evidence of cognitive impairment that persists in the remission phase of bipolar disorder; however, the extent of the deficits that occur from the first onset of the disorder remains unclear. This is the first systematic review on cognitive functioning in the early stages of bipolar I disorder. The aim of the study was to identify the patterns and degree of cognitive impairment that exists from first-episode mania. Three electronic databases (MEDLINE, PsycINFO and PubMed) were systematically searched for studies published from January 1980 to June 2014. Eligible studies were separated into two groups: acute and remission. The Newcastle-Ottawa quality assessment scale was utilised to..
View full abstractGrants
Awarded by NHMRC senior research fellowship
Awarded by NHMRC Career Development Fellowship
Awarded by NHMRC Clinical Research Training Fellowship
Awarded by NHMRC Senior Principal Research Fellowship
Funding Acknowledgements
Rothanthi Daglas has worked on a study that has received research support by Astra Zeneca. Murat Yucel is supported by a NHMRC senior research fellowship 1021973. Sue Cotton is supported by a NHMRC Career Development Fellowship 1061998. Kelly Allott is supported by a NHMRC Clinical Research Training Fellowship 628884. Michael Berk is supported by a NHMRC Senior Principal Research Fellowship 1059660 and has received Grant/Research Support from the NIH, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Rotary Health, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Meat and Livestock Board, Organon, Novartis, Mayne Pharma, Servier and Woolworths, has been a speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay and Wyeth, and served as a consultant to Astra Zeneca, Bioadvantex, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck Merck and Servier.